Figure 1
(Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein)
COVID 19 Pseudoviral Particles D614G-N501Y Coronavirus Reagent | COVID-19 reagent
SARS-CoV-2 Pseudoviral Particles, D614G-N501Y
Synonyms
COVID 19 Pseudoviral Particles D614G-N501Y Coronavirus; SARS-CoV-2 Pseudoviral Particles; D614G-N501Y; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Pseudoviral Particles D614G-N501Y; COVID-19 reagent
Form/Format
10 ml (2 tubes, 5 mL/tube), for 2 multi-well plates
Application Notes
Works perfectly for Luc pseudovirus to get robust signals 1) for screening potential inhibitors to block SARS-CoV-2 entry and viral protein translation with spike protein of SARS-CoV-2; 2) for measuring the activity of and screening for neutralizing antibody against SARS-CoV-2.
Coupled with firefly luciferase assay kit (Catalog # MBS434279), the pseudovirus infection generates robust chemiluminescent signals, 1) for screening potential inhibitor to block SARS-CoV-2 entry and viral protein translation; 2) for measuring the activity of and screening for neutralizing antibody against SARS-CoV-2-614G-N501Y (refer to the Neutralization Assay Application Note).
Coupled with firefly luciferase assay kit (Catalog # MBS434279), the pseudovirus infection generates robust chemiluminescent signals, 1) for screening potential inhibitor to block SARS-CoV-2 entry and viral protein translation; 2) for measuring the activity of and screening for neutralizing antibody against SARS-CoV-2-614G-N501Y (refer to the Neutralization Assay Application Note).
Notes
1. Amenable to HTS format (96-well, 384-well and 1536-well format). Biosafety Level 2.
2. HEK293-hACE2 stable cells are available seperately (Cat.# MBS434276)
2. HEK293-hACE2 stable cells are available seperately (Cat.# MBS434276)
Features
Robust: Excellent signal to noise (basal) ratio
Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
Easy to use: Amenable to HTS format (96-well, 384-well and 1536-well format)
Shipping Note
MBS434296 is available for shipment in the United States, Canada and European countries. Please inquire for shipment to other countries.
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
Preparation and Storage
-70 C. Shipped on dry ice. Shelf Life: Six months from the date of shipping when store at -70 degree C
Figure 1
(Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein)
Figure 1
(Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein)
Figure 2
(Figure 2. Pseudoviral Particle (PP) Infection Assays. (-): the negative control (Catalog # MBS434280); SARS-2-CoV2-614G-501Y: the PP pseudotyped with the 501Y 614G spike protein (Catalog # MBS434296).)
Figure 2
(Figure 2. Pseudoviral Particle (PP) Infection Assays. (-): the negative control (Catalog # MBS434280); SARS-2-CoV2-614G-501Y: the PP pseudotyped with the 501Y 614G spike protein (Catalog # MBS434296).)
Related Product Information for COVID-19 reagent
SARS-CoV-2 Pseudoviral Particles, replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein (the 614G-501Y variant).
The SARS-CoV-2 Pseudoviral Particles are replication-deficient Maloneymurine Leukemia Virus (MLV) pseudotyped with the SARS-CoV-2 spike protein of the 20E (EU1) variant carrying (Genbank Accession # QHD43416.1, p.501N-->Y, p.614D-->G).
It has been known that SARS coronavirus 2 (SARS-CoV-2) uses human ACE2 as the entry receptor and human proteases as the entry activators. The virus surface spike (S) protein mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to the human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and then proteolytically activated by host proteases.
Our SARS-CoV-2 Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein. They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus entry assay for SARS-CoV-2 as the S protein mediated cell entry can be conveniently measured via the luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
A new SARS-CoV-2 strain with an amino acid change at position 501 from Asn to Tyr besides the change at position 614 from Asp to Gly in the viral S protein predominated over time in locales where it was found. To support the study of this new SARS-CoV-2 strain, we established this SARS-CoV-2-614G-N501Y Pseudoviral Particles with the spike protein carrying the 501Y and 614G genotype (Genbank Accession #QHD43416.1, p.501 N->Y, p.614 D->G)
The SARS-CoV-2 Pseudoviral Particles are replication-deficient Maloneymurine Leukemia Virus (MLV) pseudotyped with the SARS-CoV-2 spike protein of the 20E (EU1) variant carrying (Genbank Accession # QHD43416.1, p.501N-->Y, p.614D-->G).
It has been known that SARS coronavirus 2 (SARS-CoV-2) uses human ACE2 as the entry receptor and human proteases as the entry activators. The virus surface spike (S) protein mediates SARS-CoV-2 entry into cells. To fulfill its function, SARS-CoV-2 spike binds to the human ACE2 (hACE2) receptor through its receptor-binding domain (RBD) and then proteolytically activated by host proteases.
Our SARS-CoV-2 Pseudoviral Particles are replication-deficient MLV pseudotyped with the SARS-CoV-2 spike protein. They also contain the ORF for firefly luciferase as a reporter. They establish a pseudovirus entry assay for SARS-CoV-2 as the S protein mediated cell entry can be conveniently measured via the luciferase reporter activity. This pseudovirus assay isolates the SARS-CoV-2 viral entry from other steps of the viral infection cycle.
A new SARS-CoV-2 strain with an amino acid change at position 501 from Asn to Tyr besides the change at position 614 from Asp to Gly in the viral S protein predominated over time in locales where it was found. To support the study of this new SARS-CoV-2 strain, we established this SARS-CoV-2-614G-N501Y Pseudoviral Particles with the spike protein carrying the 501Y and 614G genotype (Genbank Accession #QHD43416.1, p.501 N->Y, p.614 D->G)
Similar Products
Product Notes
The COVID-19 (Catalog #AAA434296) is a Reagent and is intended for research purposes only. The product is available for immediate purchase. Works perfectly for Luc pseudovirus to get robust signals 1) for screening potential inhibitors to block SARS-CoV-2 entry and viral protein translation with spike protein of SARS-CoV-2; 2) for measuring the activity of and screening for neutralizing antibody against SARS-CoV-2. Coupled with firefly luciferase assay kit (Catalog # MBS434279), the pseudovirus infection generates robust chemiluminescent signals, 1) for screening potential inhibitor to block SARS-CoV-2 entry and viral protein translation; 2) for measuring the activity of and screening for neutralizing antibody against SARS-CoV-2-614G-N501Y (refer to the Neutralization Assay Application Note). Researchers should empirically determine the suitability of the COVID-19 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "COVID 19 Pseudoviral Particles D614G-N501Y Coronavirus, Reagent" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
